Project Details
Description
Phase 1/2 Study of REGN5668 (MUC16 X CD28, a Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3)
| Status | Finished |
|---|---|
| Effective start/end date | 1/17/24 → 12/31/25 |
Funding
- REGENERON PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.